Wei Deng

Wei Deng

Auto-generated profile, based on publicly available information

Wei Deng

Cancer Clinic Haukeland University Hospital Bergen Norway

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2015 in The Analyst
Verified
Journal Article
Closed access
PDF file
WDWei Deng
Wei Deng
LHLin-Ru Hong
Lin-Ru Hong
MZMin Zhao
Min Zhao
YZYing Zhuo
Ying Zhuo
MGMing Gao
Ming Gao
An electrochemiluminescence sensor for highly selective and sensitive detection of lead(ii) ions (Pb2+) was developed taking advantage of the high specificity of the aptamer for Pb2+ and the use of both intermolecular and intramolecular co-reaction to achieve signal enhancement.

25 September 2014 in Chemical Communications
Verified
Journal Article
Closed access
PDF file
HXHuaguo Xu
Huaguo Xu
WDWei Deng
Wei Deng
FHFujian Huang
Fujian Huang
SXShiyan Xiao
Shiyan Xiao
GLGang Liu
Gang Liu
HLHaojun Liang
Haojun Liang
In this study, a single-base change discrimination strategy was developed through enhanced DNA toehold exchange reaction on a chip surface. A DNA strand with single-base change (SNPs, insertion or deletion) at an arbitrary position was clearly discriminated with nucleic acid concentrations from 0.8 nM to 1 μM through this method.

11 November 2008 in Pigment Cell & Melanoma Research
Verified
Journal Article
Closed access
PDF file
CQChuan Qin
Chuan Qin
HZHua Zhu
Hua Zhu
YCYunxin Chen
Yunxin Chen
JLJiamei Li
Jiamei Li
WDWei Deng
Wei Deng
Erwan BezardErwan Bezard
Erwan Bezard

18 October 2026 in Journal of Neuroendocrinology
Verified
Journal Article
Open access
PDF file
SMSiren Morken
Siren Morken
HSHalfdan Sorbye
Halfdan Sorbye
WDWei Deng
Wei Deng
HDHatice Toprak Dogramaci
Hatice Toprak Dogramaci
AVAndreas Venizelos
Andreas Venizelos
SKStian Knappskog
Stian Knappskog
Digestive high‐grade neuroendocrine neoplasms (HG‐NEN) are rare and heterogeneous tumours with an aggressive biology and limited treatment efficacy. Genetic intratumour heterogeneity (ITH) is a mechanism of progression and treatment resistance in other cancers, yet unexplored in digestive HG‐NEN. Next‐generation sequencing with a 360‐cancer gene panel was performed on 51 digestive HG‐NEN, suitable for multiregional sampling. The mutational status of each sample within a patient was assessed to calculate an ITH‐index, defined as the average number of discordant mutations across all pair‐wise comparisons between samples. An ITH‐index based on primary tumour samples was calculated for chemotherapy‐naïve cases: 28 neuroendocrine carcinomas (NEC), 9 mixed neuroendocrine‐non‐neuroendocrine neoplasms (MiNEN) and 3 neuroendocrine tumour grade 3 (NET G3). Median ITH‐index in NEC/MiNEN was 5, with a wide range (0–98.8). Greater heterogeneity was associated with right‐sided colonic primaries ( p = .005) and higher tumour mutational burden ( r = 0.74, p < .001). Median overall survival was 7 months longer in NEC/MiNEN with median ITH‐index above compared to below median (22.5 vs. 15.5 months, p = .077), driven mostly by patients with locoregional disease. Response to first‐line chemotherapy was not influenced by median ITH‐index. No heterogeneity was found among driver mutations in BRAF and KRAS . NET G3 displayed low heterogeneity (ITH‐index 2–3). Higher ITH‐index was not associated with shorter survival or treatment response, suggesting that genetic ITH is not the primary resistance mechanism in digestive NEC/MiNEN. Moving towards targeted treatment strategies, our data indicate that a single biopsy may underestimate ITH. BRAF and KRAS may be favourable targets as they displayed no heterogeneity.